Apellis to lay off 25% of staff, trim research in major restructuring

Apellis Pharmaceuticals is laying off one quarter of its workforce in an overhaul of its business designed to focus resources on a newly approved vision loss drug.

The job cuts announced Tuesday will affect about 225 employees. The company’s field-based sales staff and medical employees are “minimally affected” by the reorganization, which will be completed during the third quarter, Apellis said.